1. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Issue 13 (10th November 2021) Authors: Sweet, Kendra; Bhatnagar, Bhavana; Döhner, Hartmut; Donnellan, Will; Frankfurt, Olga; Heuser, Michael; Kota, Vamsi; Liu, Hongtao; Raffoux, Emmanuel; Roboz, Gail J.; Röllig, Christoph; Showel, Margaret M.; Strickland, Stephen A.; Vives, Susana; Tang, Shijie; Unger, Thaddeus J.; Joshi, Anita; Shen,... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 13(2021) Page Start: 3192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus. (4th February 2016) Authors: Tajiri, Naoki; De La Peña, Ike; Acosta, Sandra A.; Kaneko, Yuji; Tamir, Sharon; Landesman, Yosef; Carlson, Robert; Shacham, Sharon; Borlongan, Cesar V. Other Names: Ren Xiaoping guestEditor. Journal: CNS neuroscience & therapeutics Issue: Volume 22:Number 4(2016) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. Issue 2 (30th November 2021) Authors: Cornell, Robert Frank; Baz, Rachid; Richter, Joshua R.; Rossi, Adriana; Vogl, Dan T.; Chen, Christine; Shustik, Chaim; Alvarez, Mariano J.; Shen, Yao; Unger, T. J.; Ben‐Shahar, Osnat; Wang, Hongwei; Baloglu, Erkan; Senapedis, William; Ma, Xiwen; Landesman, Yosef; Bai, Xiang; Bader, Justin; Xu, Ho... Journal: American journal of hematology Issue: Volume 97:Issue 2(2022) Page Start: E54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. (March 2022) Authors: Ho, Jingshan; Heong, Valerie; Peng Yong, Wei; Soo, Ross; Ean Chee, Cheng; Wong, Andrea; Sundar, Raghav; Liang Thian, Yee; Gopinathan, Anil; Yan Pang, Mei; Koe, Priscillia; Nathan Jeraj, Santhiay; Pyar Soe, Phyu; Yar Soe, Mu; Tang, Tiffany; Ng, Matthew C.H.; Tai, David W.M.; Tan, Tira J.Y.; Xu, Ho... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. (15th June 2022) Authors: Restrepo, Paula; Bhalla, Sherry; Ghodke-Puranik, Yogita; Aleman, Adolfo; Leshchenko, Violetta; Melnekoff, David T.; Agte, Sarita; Jiang, Joy; Madduri, Deepu; Richter, Joshua; Richard, Shambavi; Chari, Ajai; Cho, Hearn Jay; Jagannath, Sundar; Walker, Christopher J.; Landesman, Yosef; Laganà, Aless... Journal: JCO precision oncology Issue: Volume 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. BIOM-26. MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM). (9th November 2020) Authors: Walker, Christopher; Shen, Yao; Mau-Soerensen, Morten; Wen, Patrick; van den Bent, Martin; Plotkin, Scott; Walenkamp, Annemiek; Green, Adam; Califano, Andrea; Chang, Hua; Tamir, Sharon; Henegar, Leah; Shacham, Sharon; Alvarez, Mariano; Landesman, Yosef; Lassman, Andrew Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Issue 1 (December 2015) Authors: Crochiere, Marsha; Kashyap, Trinayan; Kalid, Ori; Shechter, Sharon; Klebanov, Boris; Senapedis, William; Saint-Martin, Jean-Richard; Landesman, Yosef Journal: BMC cancer Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. Issue 1 (December 2016) Authors: Gravina, Giovanni; Mancini, Andrea; Sanita, Patrizia; Vitale, Flora; Marampon, Francesco; Ventura, Luca; Landesman, Yosef; McCauley, Dilara; Kauffman, Michael; Shacham, Sharon; Festuccia, Claudio Journal: BMC cancer Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Issue 1 (22nd January 2015) Authors: Neggers, Jasper E.; Vercruysse, Thomas; Jacquemyn, Maarten; Vanstreels, Els; Baloglu, Erkan; Shacham, Sharon; Crochiere, Marsha; Landesman, Yosef; Daelemans, Dirk Journal: Chemistry & biology Issue: Volume 22:Issue 1(2015) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Issue 1 (22nd January 2015) Authors: Neggers, Jasper E.; Vercruysse, Thomas; Jacquemyn, Maarten; Vanstreels, Els; Baloglu, Erkan; Shacham, Sharon; Crochiere, Marsha; Landesman, Yosef; Daelemans, Dirk Journal: Chemistry & biology Issue: Volume 22:Issue 1(2015) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗